Trials / Completed
CompletedNCT04926194
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Decidual Stromal Cells (DSC) in Treatment of Steroid-Refractory Graft-vs-host Disease in a Recipient of Matched Related Donor Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
Conditions
- Myelodysplastic/Myeloproliferative Neoplasm
- Steroid Refractory GVHD
- Allogeneic Hematopoietic Cell Transplant
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Decidual stromal cells (DSC) | DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects. |
Timeline
- Start date
- 2021-03-11
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
- First posted
- 2021-06-15
- Last updated
- 2023-01-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04926194. Inclusion in this directory is not an endorsement.